Loading patent…
AssigneeJohnson & Johnson
InventorsErling C. J. Norrby, D. Elliot Parks, Richard A. Lerner
Estimating the term…
The simian immunodeficiency virus (SIV) is genotypically and phenotypically similar to the human immunodeficiency virus type 2 (HIV-2). Both viruses display similar structural, biological, and immunological properties. The external envelope glycoprotein (EMP) and transmembrane envelope glycoprotein (TMP) appear to be formed from the cleavage of a precursor glycoprotein. Despite these similarities, a number of differences exist as evidenced by the different migratory properties of the envelope glycoproteins. The present invention discloses novel SIV peptides, obtained from the transmembrane envelope glycoprotein, that display immunological cross-reactivity with HIV-2-specific antisera. Epitope mapping studies revealed that the amino acid sequence --CAFRQVC--, which corresponds to amino acid residues 614-620, is a sine qua non for the retention of this immunological cross-reactivity. These peptides are useful in diagnostic methods for the detection of HIV-2-specific antibodies in infected patients.
A polypeptide consisting of the following amino acid sequence, AIEKYLEDQAQLNAWGCAFRQVCHTTVPWPNAS, or a polypeptide containing no more than 33 amino acid residues and differing from this sequence by no more than ten percent of the amino acid sequence, wherein said polypeptide contains the sequence --CAFRQVC--, displays immunological cross-reactivity with HIV-2 transmembrane envelope glycoprotein-specific antibodies, and fails to display immunological cross-reactivity with HIV-1 transmembrane envelope glycoprotein-specific antibodies.
A polypeptide consisting of one of the following amino acid sequences, AIEKYLEDQAQLNAWGCAFRQVC, AVEKYLKDQAQLNAWGCAFRQVC, AIEKYLKDQAQLNSWGCAFRQVC, and AIEKYLEDQAQLNAWCAFRQVC, or a polypeptide differing from one of these sequences by no more than ten percent of the amino acid sequence, wherein said polypeptide contains the sequence --CAFRQVC--, displays immunological cross-reactivity with HIV-2 transmembrane envelope glycoprotein-specific antibodies, and fails to display immunological cross-reactivity with HIV-1 transmembrane envelope glycoprotein-specific antibodies.
A polypeptide consisting of the following amino acid sequence AIEKYLEDQAQLNAWCAFRQVC.
A polypeptide consisting of the following amino acid sequence AIEKYLEDQAQLNAWGCAFRQVC.
A polypeptide consisting of the following amino acid sequence AVEKYLKDQAQLNAWGCAFRQVC.
A polypeptide consisting of the following amino acid sequence AIEKYLKDQAQLNSWGCAFRQVC.
A polypeptide consisting of one of the following amino acid sequences, AWCAFRQVCHTTVPWPNAS, SWGCAFRQVCHTSVPWVNDT, AWGCAFRQVCHTTVPWPNAS, and AWGCAFRQVCHITVPWPNAS, or a polypeptide differing from one of these sequences by no more than ten percent of the amino acid sequence, wherein said polypeptide contains the sequence --CAFRQVC--, displays immunological cross-reactivity with HIV-2 transmembrane envelope glycoprotein-specific antibodies, and fails to display immunological cross-reactivity with HIV-1 transmembrane envelope glycoprotein-specific antibodies.
A polypeptide consisting of the following amino acid sequence AWCAFRQVCHTTVPWPNAS.
A polypeptide consisting of the following amino acid sequence SWGCAFRQVCHTSVPWVNDT.
A polypeptide consisting of the following amino acid sequence AWGCAFRQVCHTTVPWPNAS.
A polypeptide consisting of the following amino acid sequence AWGCAFRQVCHITVPWPNAS.
A method of assaying for the presence of anti-HIV-2 antibodies in a body fluid sample comprising the following steps:
A diagnostic kit for the detection of anti-HIV-2 antibodies in a body fluid sample comprising a package containing a polypeptide containing no more than 33 amino acid residues and consisting of one of the following amino acid sequences, AIEKYLEDQAQLNAWGCAFRQVCHTTVPWPNAS, AIEKYLEDQAQLNAWCAFRQVC, AVEKYLKDQAQLNAWGCAFRQVC, AIEKYLKDQAQLNSWGCAFRQVC, AIEKYLEDQAQLNAWGCAFRQVC, AWCAFRQVCHTTVPWPNAS, SWGCAFRQVCHTSVPWVNT, AWGCAFRQVCHTTVPWPNAS, and AWGCAFRQVCHITVPWPNAS, or a polypeptide that differs from this sequence by no more than ten percent of the amino acid sequence, wherein said polypeptide has the sequence --CAFRQVC--, displays immunological cross-reactivity with HIV-2 transmembrane envelope glycoprotein-specific antibodies, and fails to display immunological cross-reactivity with HIV-1 transmembrane envelope glycoprotein-specific antibodies.
Dependencies are inferred from the claim text.